Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.85, $0.11 better than the analyst estimate of $0.74. Revenue for the quarter came in at $174.4 million versus the consensus estimate of $173.95 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.